Current trends and the renaissance of Alzheimer’s drug development
Historically, market authorisations for neurological diseases have had significantly lower rates of success compared with other indications. Between 2000 to 2015, the likelihood of approval for neurological drugs that entered phase 1 trials (8.4%) was …